Baseline Characteristics from a Pre-Specified Interim Analysis of a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
Effects of phosphodiesterase-5 inhibition with sildenafil on calcium waves in cardiac myocytes
Tags: cGMP-specific phosphodiesterase type 5 (PDE5) inhibitor, erectile dysfunction, pulmonary arterial hypertension, Revatio®, Viagra®
BASi Method Number SAP.1037
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
